Zheng watched the market fall below 3000 points and paid attention to the retaliatory rebound

A shares fell on Monday. As of the close, the Shanghai Composite Index fell 5.13% to 292851 points, and the 3000 point mark was officially lost. Other stock indexes are almost the same, among which the Shenzhen composite index fell 6.48% and the mass entrepreneurship and innovation index also fell more than 6%. From the disk, most stocks fell again, and the market sentiment was low.

The net outflow of funds going north on Monday was 4.397 billion yuan. In related markets, US stocks fell sharply last Friday, and the H-share Hang Seng Index fell 3.73% on Monday.

The RMB exchange rate depreciated continuously, with a significant depreciation for the fifth consecutive day on Monday. The depreciation of RMB is related to the unprecedented strengthening of the Fed's expectation of raising interest rates. The Fed is likely to raise interest rates at each interest rate meeting during the year, and the rate increase will reach 50 basis points at least several times. In terms of other non US currencies, most of them have depreciated recently.

On Monday, the central bank lowered the deposit reserve ratio of financial institutions by 0.25 percentage points and released about 530 billion yuan of long-term funds. This news is good, but everyone knows it, so it hardly plays a supporting role.

Most heavyweights, except for a few strong varieties such as China Mobile, performed weakly, including Jiangsu Hengrui Medicine Co.Ltd(600276) falling limit, China Merchants Bank Co.Ltd(600036) falling 8.64% and Contemporary Amperex Technology Co.Limited(300750) falling 6.08%.

China Mobile is mainly engaged in communication, which is very little affected by the epidemic. The rise of China Mobile may itself indicate that the market is more worried about the epidemic, because recently, the trend of the stock is often opposite to the trend of the epidemic, that is, whenever there is good news about the epidemic, the stock is likely to take profits; When worries about the epidemic rise, this stock tends to rise.

The vast majority of non heavyweights fell freely, and the bulls had little power to fight back. Few hot spots, Beijing Sl Pharmaceutical Co.Ltd(002038) and other "heparin concept stocks" performed well. Over the weekend, it was reported that at least 169 cases of hepatitis in children of unknown origin had been reported in 12 countries, according to who statistics.

On Monday, only one new share was listed and broke, but recently there have been so many such phenomena that almost no one has noticed. With regard to the frequent breaking of new shares, the Shanghai Stock Exchange has organized relevant institutions to hold a seminar. Personally, I think that since the exchange has held such seminars, it can only explain one situation, that is, the relevant parties are not happy with the current phenomenon of generally high pricing of new shares. Therefore, investors don't have to worry about what is said at the seminar. According to general experience, I feel that the probability of IPO price will decrease in the future.

When the market falls to this share, from the usual experience, major integer checkpoints, whether conquered or lost, will generally have repetition. Personally, I feel that the market has a considerable opportunity to return to the 3000 mark in the short term. Based on this consideration, it is suggested that investors hold shares and wait-and-see, and those with light positions can take advantage of panic to pick up some goods. Even if the current situation is not "no pole", I believe it is not too far away!

The next few days are the intensive period of annual and quarterly reports. Many heavyweights will also publish statements at this time, and unpredictable individual stocks will rise and fall sharply. Investors should pay attention to the report factors when looking at the market, and sometimes should not be over interpreted. For example, Jiangsu Hengrui Medicine Co.Ltd(600276) fell sharply on Monday because the performance was lower than expected. Investors have to analyze specific stocks and should not sell other pharmaceutical stocks without brains.

- Advertisment -